NEW YORK, Dec. 10 – Swiss pharmaceutical company Roche said Monday it was merging its Nippon Roche subsidiary with Japanese pharmaceutical company Chugai in a new entity that will be named Chugai Pharmaceutical. 

Chugai chairman and CEO, Osamu Nagayama, will be the chairman and CEO of the merged company. Wataru Ogawa, Nippon Roche’s current president and CEO, will be nominated for a seat on the board of directors. Roche will hold 50.1 percent of the company’s shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.